Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

BACKGROUND: ) inhibitor with potent pan-human-coronavirus activity in vitro. CONCLUSIONS: Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 METHODS: We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.
• 2 Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated.
• 3 RESULTS: copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: